{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T14:34:30Z","timestamp":1742999670058,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":34,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781461485193"},{"type":"electronic","value":"9781461485209"}],"license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-4614-8520-9_5","type":"book-chapter","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T21:01:25Z","timestamp":1380142885000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Staging of Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Vivek","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"key":"5_CR00051","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860\u201373.","journal-title":"N Engl J Med"},{"key":"5_CR00052","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0002-9343(73)90116-2","volume":"54","author":"G Costa","year":"1973","unstructured":"Costa G, Engle RL, Schilling A, et al. Melphalan and prednisone: an effective combination ofor the treatment of multiple myeloma. Am J Med. 1973;54:589\u201399.","journal-title":"Am J Med"},{"key":"5_CR00053","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/bmj.2.5757.324","volume":"2","author":"R Peto","year":"1971","unstructured":"Peto R. Urea, albumin, and response rates. Br Med J. 1971;2:324.","journal-title":"Br Med J"},{"key":"5_CR00054","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/pgmj.47.552.635","volume":"47","author":"AA Dawson","year":"1971","unstructured":"Dawson AA, Ogston D. Factors influencing the prognosis in myelomatosis. Postgrad Med J. 1971;47:635\u20138.","journal-title":"Postgrad Med J"},{"key":"5_CR00055","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I","volume":"36","author":"R Alexanian","year":"1975","unstructured":"Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer. 1975;36: 1192\u2013201.","journal-title":"Cancer"},{"key":"5_CR00056","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0002-9343(67)90074-5","volume":"42","author":"PP Carbone","year":"1967","unstructured":"Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med. 1967;42:937\u201348.","journal-title":"Am J Med"},{"key":"5_CR00057","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"5_CR00058","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1172\/JCI106327","volume":"49","author":"SE Salmon","year":"1970","unstructured":"Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest. 1970;49:1114\u201321.","journal-title":"J Clin Invest"},{"key":"5_CR00059","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2141.1979.tb01124.x","volume":"42","author":"RK Woodruff","year":"1979","unstructured":"Woodruff RK, Wadsworth J, Malpas JS, Tobias JS. Clinical staging in multiple myeloma. Br J Haematol. 1979;42:199\u2013205.","journal-title":"Br J Haematol"},{"key":"5_CR000510","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V55.6.1011.1011","volume":"55","author":"G Merlini","year":"1980","unstructured":"Merlini G, Waldenstrom JG, Jayakar SD. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood. 1980;55:1011\u20139.","journal-title":"Blood"},{"key":"5_CR000511","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJM197910043011402","volume":"301","author":"DE Bergsagel","year":"1979","unstructured":"Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743\u20138.","journal-title":"N Engl J Med"},{"key":"5_CR000512","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/978-3-642-81249-1_5","volume":"65","author":"D Belpomme","year":"1978","unstructured":"Belpomme D, Simon F, Pouillart P, et al. Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone. Recent Results Cancer Res. 1978;65:28\u201340.","journal-title":"Recent Results Cancer Res"},{"key":"5_CR000513","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0609.1989.tb01500.x","volume":"51","author":"M Cavo","year":"1989","unstructured":"Cavo M, Galieni P, Grimaldi M, et al. Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: a multivariate regression analysis of 163 untreated patients. Eur J Haematol Suppl. 1989;51:99\u2013104.","journal-title":"Eur J Haematol Suppl"},{"key":"5_CR000514","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","volume":"42","author":"BG Durie","year":"2006","unstructured":"Durie BG. The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system. Eur J Cancer. 2006;42:1539\u201343.","journal-title":"Eur J Cancer"},{"key":"5_CR000515","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/bjc.1980.330","volume":"42","author":"Medical Research Council\u2019s Working Party on Leukemia in Adults","year":"1980","unstructured":"Medical Research Council\u2019s Working Party on Leukemia in Adults. Prognostic features in the third MRC myelomatosis trial. Medical Research Council\u2019s Working Party on Leukaemia in Adults. Br J Cancer. 1980;42:831\u201340.","journal-title":"Br J Cancer"},{"key":"5_CR000516","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/JCO.1986.4.1.80","volume":"4","author":"R Bataille","year":"1986","unstructured":"Bataille R, Durie BG, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol. 1986;4:80\u20137.","journal-title":"J Clin Oncol"},{"key":"5_CR000517","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.1985.3.2.229","volume":"3","author":"R Bataille","year":"1985","unstructured":"Bataille R, Legendre C, Sany J. Acute effects of salmon calcitonin in multiple myeloma: a valuable method for serial evaluation of osteoclastic lesions and disease activity\u2014a prospective study of 125 patients. J Clin Oncol. 1985;3:229\u201336.","journal-title":"J Clin Oncol"},{"key":"5_CR000518","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2141.1989.tb04314.x","volume":"72","author":"J Blade","year":"1989","unstructured":"Blade J, Rozman C, Cervantes F, Reverter JC, Montserrat E. A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol. 1989;72:507\u201311.","journal-title":"Br J Haematol"},{"key":"5_CR000519","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2141.1985.tb07366.x","volume":"59","author":"W Gassmann","year":"1985","unstructured":"Gassmann W, Pralle H, Haferlach T, et al. Staging systems for multiple myeloma: a comparison. Br J Haematol. 1985;59:703\u201311.","journal-title":"Br J Haematol"},{"key":"5_CR000520","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","volume":"75","author":"BG Durie","year":"1990","unstructured":"Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75:823\u201330.","journal-title":"Blood"},{"key":"5_CR000521","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0277-5379(83)90030-5","volume":"19","author":"R Bataille","year":"1983","unstructured":"Bataille R, Vincent C, Revillard JP, Sany J. Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance. Eur J Cancer Clin Oncol. 1983;19:1075\u201380.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"5_CR000522","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/bjc.1983.13","volume":"47","author":"JA Child","year":"1983","unstructured":"Child JA, Crawford SM, Norfolk DR, O\u2019Quigley J, Scarffe JH, Struthers LP. Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer. 1983;47:111\u20134.","journal-title":"Br J Cancer"},{"key":"5_CR000523","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. Nature. 1988;332:83\u20135.","journal-title":"Nature"},{"key":"5_CR000524","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","volume":"73","author":"B Klein","year":"1989","unstructured":"Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73: 517\u201326.","journal-title":"Blood"},{"key":"5_CR000525","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2141.1994.tb04748.x","volume":"86","author":"A Tienhaara","year":"1994","unstructured":"Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol. 1994;86: 391\u20133.","journal-title":"Br J Haematol"},{"key":"5_CR000526","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","volume":"80","author":"R Bataille","year":"1992","unstructured":"Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733\u20137.","journal-title":"Blood"},{"key":"5_CR000527","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V85.2.448.448","volume":"85","author":"JF San Miguel","year":"1995","unstructured":"San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 1995;85: 448\u201355.","journal-title":"Blood"},{"key":"5_CR000528","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V59.1.43.43","volume":"59","author":"J Latreille","year":"1982","unstructured":"Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood. 1982;59:43\u201351.","journal-title":"Blood"},{"key":"5_CR000529","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V72.1.219.219","volume":"72","author":"PR Greipp","year":"1988","unstructured":"Greipp PR, Katzmann JA, O\u2019Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72:219\u201323.","journal-title":"Blood"},{"key":"5_CR000530","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","volume":"81","author":"PR Greipp","year":"1993","unstructured":"Greipp PR, Lust JA, O\u2019Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382\u20137.","journal-title":"Blood"},{"key":"5_CR000531","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"5_CR000532","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3324\/haematol.11637","volume":"93","author":"VT Hungria","year":"2008","unstructured":"Hungria VT, Maiolino A, Martinez G, et al. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica. 2008;93:791\u20132.","journal-title":"Haematologica"},{"key":"5_CR000533","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.bbmt.2006.04.006","volume":"12","author":"H Kim","year":"2006","unstructured":"Kim H, Sohn HJ, Kim S, et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. Biol Blood Marrow Transplant. 2006;12:837\u201344.","journal-title":"Biol Blood Marrow Transplant"},{"key":"5_CR000534","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/leu.2009.61","volume":"23","author":"PN Hari","year":"2009","unstructured":"Hari PN, Zhang MJ, Roy V, et al. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009; 23:1528\u201334.","journal-title":"Leukemia"}],"container-title":["Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-8520-9_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:37:43Z","timestamp":1716007063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4614-8520-9_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,4]]},"ISBN":["9781461485193","9781461485209"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-8520-9_5","relation":{},"subject":[],"published":{"date-parts":[[2013,9,4]]},"assertion":[{"value":"4 September 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}